NCT02118012View on ClinicalTrials.gov

Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

March 20, 2014

Primary Completion Date

March 20, 2014

Study Completion Date

September 20, 2016

Conditions
Chronic Hepatitis C
Interventions
DRUG

Chlorcyclizine HCl

Chlorcyclizine HCl (75 mg twice daily)

DRUG

Ribavirin

RBV was dosed via a weight-based regimen of 1000 mg daily\<75 kg and 1200 mg daily ≥75 kg.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT02118012 - Evaluation of Safety, Tolerability, and Antiviral Activity of Chlorcyclizine HCl in Patients With Chronic Hepatitis C | Biotech Hunter | Biotech Hunter